All GLG News Analyses Filed Under: Endocrinology

HRT is likely to help glucose metabolism as it does lipid profiles.However not in favor by most patients or physiciansHRT's rise in expectations in the late 90's and subsequent negative press may make it a last resort forever.

During ADOPT trial, fractures were more commonly observed in female patients receiving rosiglitazone (NYSE: GSK) rather than either metformin or glyburide.Independent safety committee reviewed an interim analysis of fractures in another large clinical trial and preliminary analysis demonstrated similar...

A mild negative, at worst.

MannKind's investigational inhaled insulin product for prandial insulin delivery for Type 1 and Type 2 diabetics is based on its proprietary insulin Technosphere® formulation and MedTone® inhaler. "Technosphere Insulin closely mimics normal insulin release seen in non-diabetic patients, has...

By acquiring BioRexis, Pfizer receives access not only to potential long-acting GLP-1 receptor agonist, but also to proprietary protein engineering technologies based upon human transferrin that provide novel therapeutic agents with substantially longer duration of action than synthetic peptides.

* Rimonabant has promising science but certain side effects, especially psychological side effects* Treating diabetes has a certain future, while treating obesity with pharmacologic mechanisms has certain, well-known cautions* Differently than what is stated here, there are 2 other diabetes drugs on...

With the new onset of the obesity and diabetes epidemics, a drug that will treat both and decrease factors related to the metabolic syndrome will be gladly welcomed. Cardiovascular disease is our number one killer. Reducing risk factors, which this drug should do, will be a greatly needed addition to...

The finding of higher density of Firmicutes bacteria in the guts of obese mice and even humans is a "scientific" curiosity.It is too early for this finding to have any therapeutic implications and it is not known if it is cause or effect of obesity.Genetic determinants of obesity and lifestyle are still...

Inhaled insulin (exubera) has a novel delivery mode, but has short half life.Its use will be limited mostly to very few patients with type I diabetes who have true needle phobia and are quite motivated to stick with the three times a day dosing and the pretty sophisticated delivery device. Insulin...

Acomplia (Rimonabant) is a novel selective CB1 endocannibinoid receptor antagonist that was developed as an anti-obesity drug to promote weight loss.This drug is not a stimulant - it works on receptors in the brain responsible for the desire to eat.In clinical trials, rimonabant has been shown...